Komori
Astellas Pharma (4503) · InitiativeRestated

Product Reliability and Greater Transparency in Clinical Trial Information

First written in FY2016. 1 of 2 entries say "Restated". Latest entry: FY2017.

2entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016 – FY20172016: 120162017: 12017
Same theme, other companies
Enhancing Product Reliability and Transparency of Clinical Trial InformationA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2017RestatedAnnual report

    「製品の信頼性向上のための対応のほか、治験情報等の透明化を含む情報開示体制の強化に取り組んでいきます。」

    製品信頼性の向上と治験情報等の透明化を含む開示体制強化を引き続き掲げている。
  2. FY2016First statedAnnual report

    「製品の信頼性向上のための対応のほか、治験情報等の透明化を含む情報開示体制の強化に取り組んでいきます。」

    製品の信頼性向上と、治験情報を含む情報開示体制の強化をOperational Excellenceの施策として示している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Product Reliability and Greater Transparency in Clinical Trial Information | Astellas Pharma Inc. (4503) | Komori